The Latest Breaking News from Aptinyx

 

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Aptinyx (NASDAQ:APTX) reported its Q4 earnings results on Wednesday, March 23, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Aptinyx beat estimated earnings by 17.14%, reporting an EPS of $-0.29 versus an estimate of $-0.35.

Aptinyx (NASDAQ:APTX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate that Aptinyx will report an earnings per share (EPS) of $-0.35.